Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Myrexis

Status and phase: Completed; Phase 1

Conditions: Refractory Solid Tumors

Treatments: Drug: MPC-6827

Study type: Interventional

Funder types: Industry

Identifiers

NCT00394446

MPC6827-04-001

Details and patient eligibility

About

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Advanced or Metastatic Cancer
2. Measurable / Evaluable Disease
3. Karnofsky score greater than or equal to 70%
4. Adequate Hematology / Organ function
5. No Baseline peripheral or central neuropathy above grade 1

Exclusion criteria

1. Hypersensitivity to Cremophor EL
2. Pregnant or Lactating
3. Spinal Cord Compression
4. Pre-existing Dementia / Cognitive Disfunction
5. Require Neupogen or Neulasta to Maintain Neutrophil Count
6. Have Primary Brain Cancer
7. Have history of Ischemic Heart Disease
8. Have Diabetes

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)